Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Go back to Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
(NASDAQ: OCGN) Delayed: 1.38 +0.09 (6.98%)
Previous Close $1.29    52 Week High
Open $1.28    52 Week Low
Day High $1.43    P/E N/A 
Day Low $1.28    EPS
Volume 8,178,368